Caladrius Biosciences (CLBS) Lowered to “Sell” at Zacks Investment Research

Caladrius Biosciences (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Caladrius Biosciences in a report on Friday, November 10th.

Caladrius Biosciences (NASDAQ:CLBS) opened at $3.92 on Wednesday. Caladrius Biosciences has a fifty-two week low of $2.63 and a fifty-two week high of $7.79. The company has a market cap of $37.32, a PE ratio of -1.89 and a beta of 1.59.

Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. research analysts predict that Caladrius Biosciences will post -2.33 EPS for the current year.

An institutional investor recently raised its position in Caladrius Biosciences stock. Vanguard Group Inc. increased its holdings in Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 155,380 shares of the biotechnology company’s stock after buying an additional 4,163 shares during the period. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.41% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://sportsperspectives.com/2018/01/12/caladrius-biosciences-clbs-lowered-to-sell-at-zacks-investment-research.html.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply